Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI

The recent first global approval of delafloxacin has been reviewed in detail in the First Global Approval report in Adis journal Drugs[1], based on the development milestones tracked in AdisInsight.[2] Continue reading “Delafloxacin (Baxdela™): First Global Approval – Flexible dosing, broad spectrum coverage, effective against resistant pathogens – appealing characteristics for the treatment of ABSSSI”